Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Stenocare ASOCSE:STENO -6.85%36 3-1 Month Momentum % is -17.18% as of Sep. 11, 2026. GuruFocus rates OCSE:STENO with a GF Score™ of 36/100 and a GF Value™ of kr2.56 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,023 Drug Manufacturers companies, Stenocare AS ranks worse than 88.95% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-11), Stenocare AS's 3-1 Month Momentum % is -17.18%.
The industry rank for Stenocare AS's 3-1 Month Momentum % or its related term are showing as below:
OCSE:STENO's 3-1 Month Momentum % is ranked worse than 88.95% of 1023
companies
in the Drug Manufacturers industry
Industry Median: 3.13
vs OCSE:STENO: -17.18
Stenocare AS (OCSE:STENO) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Stenocare AS 3-1 Month Momentum % Related Terms
OCSE:STENO vs ZTS, UTHR, VTRS: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Stenocare AS's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stenocare AS 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Stenocare AS's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Stenocare AS's 3-1 Month Momentum % falls into.
Stenocare AS (OCSE:STENO) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stenocare AS (OCSE:STENO) has a 3-1 Month Momentum % of -17.18% as of Sep. 11, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Stenocare AS and its competitors. According to the industry distribution chart, Stenocare AS ranks #910 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 89%.
Is Stenocare AS's 3-1 Month Momentum % too high?
Stenocare AS's current 3-1 Month Momentum % is -17.18%. Based on the distribution chart, Stenocare AS ranks #910 out of 1023 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Stenocare AS has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Stenocare AS's 3-1 Month Momentum % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Stenocare AS ranks #910 out of 1023 companies for 3-1 Month Momentum %. This places Stenocare AS in the lower half of its industry. The industry median 3-1 Month Momentum % is 3.13. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
The median 3-1 Month Momentum % among Drug Manufacturers companies is 3.13, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Stenocare AS and its competitors. For the Drug Manufacturers industry, the median 3-1 Month Momentum % is 3.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stenocare AS's current 3-1 Month Momentum % is -17.18%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stenocare AS stock overvalued right now?
Based on GuruFocus' analysis, Stenocare AS (OCSE:STENO) is currently considered Possible Value Trap. The stock's GF Value™ is kr2.56, compared to a current price of kr0.90 — trading 64.9% below its estimated fair value. The current 3-1 Month Momentum % is -17.18%. Stenocare AS's overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Stenocare AS (OCSE:STENO), the current 3-1 Month Momentum % is -17.18% as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stenocare AS (OCSE:STENO) Overvalued in 2026?
Based on GuruFocus' analysis, Stenocare AS stock appears to be undervalued.
The current stock price of kr0.90 is trading 64.9% below its estimated GF Value™ of kr2.56.
GuruFocus considers Stenocare AS to be Possible Value Trap.
Key valuation signals for OCSE:STENO:
3-1 Month Momentum %: -17.18%
GF Value™: kr2.56 vs. price of kr0.90 (64.9% below fair value)
No single metric tells the full story. See the OCSE:STENO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stenocare AS is a Danish company engaged in the cultivation and production of medical cannabis products through pharmacies and hospitals. The company's business operations include the distribution and sales of imported products to several markets which also includes local cultivation and production of its medical cannabis products. Stenocare is well positioned to become a market leader in Denmark and a vendor in Europe. The company is a supplier of medical cannabis oil for patients in Denmerk, Sweden, UK, Australia and Norway.
36GF Score
Get the complete analysis for OCSE:STENO
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:STENO has been successfully added to your 
